Evaluating Novel Target Trial Data, Isotope Selection, Dosimetry Assessment, & Share Regulatory Insights to Drive & Achieve RLT Potential as First-Line & Combination Therapies in Modern Oncology.
Targeted radiopharmaceuticals have entered a new era. Clinical success is accelerating investment, pipelines are rapidly expanding beyond lutetium into next-generation alpha emitters and novel targets, and developers are racing to bring transformative radioligand therapies to patients. As the field matures, the industry’s greatest challenges involve clinical translation, isotope availability, manufacturing scale-up and regulatory alignment.
The 8th Targeted Radiopharmaceuticals Summit Europe unites the scientific, clinical, manufacturing, regulatory and commercial leaders driving this transformation to build the blueprint for Europe’s next generation of targeted radiopharmaceuticals.
Uniting TCE Leaders to Optimise Target Selection & Innovate Cell Engager Design to Accelerate Transformative Immunotherapies from Research Towards Clinical Approval.
Returning to London in December 2026, the 2nd T-Cell Engager Therapeutics Summit Europe will bring together industry pioneers and leading experts to showcase the latest advances in target selection technologies, innovative engager designs and strategies for overcoming safety challenges. Across 3 jam-packed days, attendees will gain data-driven insights into accelerating the development of T-cell engager therapeutics across both oncology and autoimmune disease landscapes.